Nothing published in preprint* form was interesting enough for me to take a deep dive into, but there were a few studies worth mentioning, and here they are. One paper suggested that tocilizumab, an inhibitor of interleukin-6 (IL-6), reduces mortality from COVID-19. Whether patients received it, after some basic inclusion criteria, was left to the judgment of the physician, and 77 who received it were compared to 94 who did not. The study wasn't randomized, so it doesn't give us clear evidence of cause-and-effect. Nevertheless, the IL-6 blocker looks promising. Admission to the ICU was over 60% lower in those who received tocilizumab, 10.3% vs 27.6%, and the number requiring ventilation was 0% instead of 13.8%. I
A Few Interesting COVID-19 Studies From Today
A Few Interesting COVID-19 Studies From Today
A Few Interesting COVID-19 Studies From Today
Nothing published in preprint* form was interesting enough for me to take a deep dive into, but there were a few studies worth mentioning, and here they are. One paper suggested that tocilizumab, an inhibitor of interleukin-6 (IL-6), reduces mortality from COVID-19. Whether patients received it, after some basic inclusion criteria, was left to the judgment of the physician, and 77 who received it were compared to 94 who did not. The study wasn't randomized, so it doesn't give us clear evidence of cause-and-effect. Nevertheless, the IL-6 blocker looks promising. Admission to the ICU was over 60% lower in those who received tocilizumab, 10.3% vs 27.6%, and the number requiring ventilation was 0% instead of 13.8%. I